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ABSTRACT
Sixty years ago, Steele, Richardson and Olszewski 
designated progressive supranuclear palsy (PSP) 
as a new clinicopathological entity in their seminal 
paper. Since then, in addition to the classic Richard-
son’s syndrome (RS), different clinical phenotypic 
presentations have been linked with this four-repeat 
tauopathy. The clinical heterogeneity is associated 
with variability of regional distribution and severity 
of abnormal tau accumulation and neuronal loss. In 
PSP subtypes, the presence of certain clinical point-
ers may be useful for antemortem prediction of the 
underlying PSP-tau pathology. Midbrain atrophy on 
conventional MRI correlates with the clinical phe-
notype of RS but is not predictive of PSP pathology. 
Cerebrospinal fluid biomarkers and tau ligand posi-
tron emission tomography are promising biomark-
ers of PSP. A multidisciplinary approach to meet the 
patients’ complex needs is the current core treat-
ment strategy for this devastating disorder. 
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INTRODUCTION
In 1964, an unusual syndrome of supranuclear 
gaze palsy, progressive axial rigidity, pseudobulbar 
palsy and mild dementia was described.1 In this 
seminal paper, extensive subcortical neurofibrillary 
degeneration predominantly found in the globus 
pallidus, subthalamic nucleus, substantia nigra and 
cerebellar dentate nucleus were characterised as the 
pathological substrates of the new clinicopathologic 
entity of progressive supranuclear palsy (PSP), also 
known as Steele-Richardson-Olszewski syndrome.1 
Steele2 predicted that ‘clinical variants of the syn-
drome are likely to occur as the disease affects dif-
ferent nuclei at different times and to different de-
grees’. Since then, increasing recognition of pheno-
typic heterogeneity has been linked to the regional 
severity of abnormal tau accumulation and neuronal 
loss,3 although all PSP regardless of clinical variants 
share similar neuropathologic features and fulfill the 
neuropathologic criteria for PSP.4 In most cases, the 
evaluation of histological findings cannot lead to 
deduction of the clinical phenotype due to signifi-
cant overlap in regional pathologies. Tau-immuno-
reactive tufted astrocytes are the pathognomonic 
histological feature, commonly observed in the pre-
central gyrus, striatum, superior colliculus, thalamus, 
subthalamic nucleus and red nucleus (Figure 1). 
Globose neurofibrillary tangles (NFTs) in the brain 
stem nuclei, flame-shaped NFTs, coiled bodies, neu-
ronal loss and gliosis are other accompanying find-
ings.3 PSP-tau is comprised predominantly of 4-re-
peat tau.5 High frequency of concomitant patholo-
gies such as Alzheimer disease and argyrophilic gr-
ains in PSP may partly contribute to the clinical he-
terogeneity.6
The aim of this review is to apply the recent ad-
vances in PSP in the clinical approach of patients in-
cluding bedside examination, investigation and ma-
nagement.
EPIDEMIOLOGY, NATURAL  
HISTORY AND AETIOLOGY
The prevalence of PSP is 5.8–6.5 per 100,000.7-9 
Patients with the classic PSP-Richardson syndrome 
(PSP-RS) usually develop their first symptoms in 
their mid-60s and the condition gradually progress-
es from symptom onset to death over an average of 
7 years.10 Clinical subtypes of PSP-parkinsonism 
(PSP-P) and PSP-pure akinesia with gait freezing 
(PSP-PAGF) have a more benign course with a sur-
vival period of a decade or more11 and both subtypes 
have an overall tau burden less than those in PSP-
RS and the distribution of abnormal tau is relatively 
restricted to the brain stem.12,13 The phenotypes of 
PSP-P and PSP-PAGF are sometimes referred as the 
‘brain stem’ variants of PSP, as opposed to the ‘cor-
tical’ variants which present with predominant cor-
tical features including PSP-corticobasal syndrome 
(PSP-CBS), PSP-behavioural variant of frontotem-
poral dementia (PSP-bvFTD) and PSP-progressive 
non-fluent aphasia (PSP-PNFA).3
A study of disease progression in 110 pathologi-
cally confirmed PSP showed that intervals from dis-
ease onset to the development of frequent falls was 
3.9 (± 2.5) years, cognitive impairment 4.2 (± 2.9) 
years, unintelligible speech 6 (± 2.5) years, residen-
tial care 6.1 (± 3.0) years, urinary catheter 6.3 (± 3.1) 
years, wheelchair dependence 6.4 (± 2.7) years and 
severe dysphagia 6.4 (± 2.4) years.14 A PSP rating 
scale with 28 items in six categories provides useful 
quantitative assessment in clinical practice and re-
search trials.15 Mean progression rate is + 11.3 points 
per year with the scores ranging from 0–100. The 
motor subscale of the Unified Parkinson’s Disease 
Rating Scale is also a reliably clinimetric scale to as-
sess motor disability in PSP.16
The cause of PSP is unknown. Advanced age is 
the only established risk factor.7 To date, head inju-
Figure 1. Tau immunohistochemistry using anti-tau 
(AT8) antibody shows tufted astrocytes in the frontal 
cortex of a case with pathologically confirmed progres-
sive supranuclear palsy (× 20 magnification). 
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ry has not been established as a risk factor of PSP.17 
A prevalence study found 24% of PSP cases had 
early histological evidence of chronic traumatic en-
cephalopathy (CTE),18 a neurodegenerative conse-
quence of repetitive head injury previously referred 
as dementia pugilistica in boxers.19 Whether the 
CTE-tau pathology began following the onset of 
PSP as a result of frequent falls is not known.20 Geo-
graphical clusters of patients with PSP-like syndrome 
on Guam and Guadeloupe have probable links to 
environmental causes.21,22 These neurodegenerative 
tauopathies have clinical features atypical to the clas-
sic RS and the Guam-parkinsonian dementia com-
plex is pathologically distinct from PSP.23
Frontotemporal dementia with parkinsonism due 
to autosomal dominant mutations in the MAPT gene 
(FTDP-17T) is clinically and pathologically hetero-
geneous.24 Specifically, FTDP-17T due to exon 10 
coding or splicing shares the most similarity to PSP, 
both clinically and pathologically.25 Although PSP is 
considered a sporadic condition, FTDP-17T proba-
bly provides the best clues as to the etiology of PSP.26 
The strong association between the H1c haplo-
type and PSP was confirmed by a genome-wide 
study (GWAS) of PSP which identified the presence 
of independent association signals at the MAPT lo-
cus representing both the H1/H2 haplotypes and the 
rs242557 MAPT SNP, related to the H1c sub-hap-
lotype.27 Non-MAPT risk factors associated with 
PSP, EIF2AK3, MOBP and STX-6, were also found 
in the PSP GWAS.27 The protein functions of these 
candidate genes provide insights to the biochemical 
basis of the pathophysiological mechanisms. 
The findings of seeding and spreading of trans-
missible tau neuropathology in transgenic mouse 
brains including PSP-tau support the notion of a 
cell-to-cell propagation mechanism of different ‘st-
rains’ of fibrillary tau leading to distinct patterns of 
neuronal and glial pathology which is disease- and 
neural network-specific.28
PSP-RS
The current operational criteria are only limited 
to the clinical diagnosis of PSP-RS and no accepted 
guidelines for the clinical diagnosis of other pheno-
typic presentations of PSP are currently available 
(Table 1). The National Institute of Neurological Dis-
orders and Stroke (NINDS) criteria for ‘probable’ 
PSP describes a gradual progressive disorder with 
an age of onset over 40 years, falls within the first year, 
vertical supranuclear gaze palsy or slowing of verti-
cal saccades.29 
Patients in their late 50’s or 60’s usually present 
with insidious onset of non-specific symptoms such 
as blurred vision, dry eyes, photophobia, dizziness, 
unsteadiness, falls and fatigue. Family members may 
comment on apathy, depression, irritability and soft-
ening of speech. Predominant behavioural and cog-
nitive features are the presenting features without 
motor symptoms in a fifth of patients indistinguish-
able to frontotemporal dementia. Correct diagnosis is 
commonly delayed to 3–4 years after symptom onset.7 
As the disease progresses, the characteristic fea-
Table 1.  Clinical features of PSP-RS, PSP-P, PSP-PAGF, PSP-CBS, PSP-PNFA, PSP-bvFTD, PSP-C, Parkinson’s disease, and MSA-P
PSP-RS PSP-P PSP-PAGF PSP-CBS PSP-PNFA PSP-bvFTD PSP-C
Parkinson’s 
disease
MSA-P
Rigidity Axial > limb Limb > axial Axial Limb > axial + + Axial > limb Limb > axial Limb > axial
Early postural instability and/or falls +++ - + -/+ - - +++ - -
Early eye movement abnormalities +++ ++ +/- ++ + + +++ - -/+
Early cognitive decline ++ - - +++ +++ +++ ++ - -
Early frontal behaviour ++ - - ++ ++ +++ ++ -/+ -/+
Non-fluent aphasia and/or apraxia
   of speech
+ - - ++ +++ ++ - - -
Limb dystonia + + -/+ +++ + +
(limb and 
truncal 
ataxia)
+ +
Pyramidal and Babinski’s signs + + + ++ + + - - ++
Levodopa response - ++ - - - - - +++ ++
Dysautonomia - - - - - - - + +++
MSA-P: multiple system atrophy-parkinsonism, PSP: progressive supranuclear palsy, PSP-C: PSP with predominant cerebellar ataxia, PSP-CBS: PSP-cortico-
basal syndrome, PSP-bvFTD: PSP-behavioural variant of frontotemporal dementia, PSP-P: PSP-parkinsonism, PSP-PAGF: PSP-pure akinesia with gait freez-
ing, PSP-PNFA: PSP-progressive non-fluent aphasia, PSP-RS: PSP-Richardson’s syndrome, -: absent, -/+: rare, +: occasional or mild, ++: usual or moderate, 
+++: frequent or severe.
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tures of postural instability with unprovoked falls, 
mostly backwards, become disabling which render 
the patients wheelchair-bound to prevent injuries 
resulting from falls. Gait is slightly wide-based and 
may initially be misdiagnosed as cerebellar ataxia. 
Gait ignition failure and freezing of gait are com-
mon. Frontalis overactivity, reduced eye blink, focal 
dystonia of the procerus muscle (procerus sign), 
axial rigidity, upright extended posture and some-
times, retrocollis, give a characteristic appearance 
which can be immediately recognisable to an expe-
rienced neurologist as the patient enters the consul-
tant room. Motor recklessness caused by frontal 
impairment further contributes to falls and injuries. 
Repetitive finger tapping is small in amplitude (hy-
pokinesia) with good speed and without decre-
ment, which differs distinctively from criteria-de-
fined bradykinesia with fatigue and decrements in 
Parkinson’s disease.30 Orthostatic hypotension is 
not a feature of PSP but urinary symptoms includ-
ing urgency, retention and incontinence, constipa-
tion and erectile dysfunction are common as the 
disease progresses. Sleep abnormalities including 
rapid eye movement (REM) sleep behavior disor-
der, are more commonly observed in synucleinopa-
thies such as multiple system atrophy (MSA) and 
Parkinson’s disease, but can also occur in up to 35% 
of patients with PSP.31 
Inability to read is a frequent and disabling symp-
tom due to saccadic eye movement disorder. Sq-
uare-wave jerks, in which the eyes oscillate hori-
zontally across the midline during visual fixation is 
an early eye sign. It is also observed in MSA, cere-
bellar disorders and occasionally in Parkinson’s dis-
ease.32 Careful ocular examination also reveals im-
pairment of convergence and defective pupillary 
responses with accommodation.33 Slowing of verti-
cal saccades with or without ‘round the houses’ sign 
(curved trajectory of vertical saccades)34 are fol-
lowed by supranuclear gaze palsy with restriction 
of the range of vertical gaze.35 Pretarsal blepharo-
spasm and apraxia of eyelid opening are other 
common features.36 Visual grasping (eye deviation 
and intermittent head turns towards object the pa-
tients have walked past) is sometimes mistaken as 
cervical dystonia.37-40
Disinhibition in PSP can be demonstrated by bi-
lateral impaired antisaccade task (inability to look 
in the direction opposite to the visual stimulus plac-
es on a horizontal visual plane which is usually the 
examiner’s waving hands on either side of the pa-
tient) and impaired Stroop test performance.40
Frontal lobe dysfunction is the most consistent 
deficit in PSP.41 Behavioural change, apathy, execu-
tive dysfunction, emotional lability with uncontrol-
lable laughter or crying, aggressive outbursts, com-
pulsive behaviour and inappropriate sexual behavior 
are sometimes encountered. The frontal assessment 
battery is useful to capture frontal impairments with 
lexical fluency and Luria motor sequencing being 
the two most useful parameters.42 A score of less than 
12 (out of 18) has a sensitivity of 77% and specifici-
ty of 87% in differentiating frontal lobe dysfunction 
from amnestic dementia.43 Letter fluency is more im-
paired than semantic fluency in PSP-RS in contrast 
to Alzheimer’s disease.44 Inability to recall more than 
seven initial letter words supports the diagnosis of 
PSP-RS.45 Positive applause sign (when the patient 
claps hands more than 3 times exceeding the exam-
iner’s demonstration and instruction) is more com-
monly observed in PSP than in corticobasal degen-
eration (CBD), FTD and Parkinson’s disease and is a 
sign of motor perseveration.46
Despite executive and inhibition deficits being 
the most prominent cognitive features, a third of 
PSP patients also have memory impairment includ-
ing poor episodic memory and visuospatial func-
tions.41 The Addenbrooke’s cognitive examination-
revised (ACE-R)45 and the dementia rating scales47 
are more sensitive tools than the mini-mental state 
examination to capture these deficits. 
In the late stages, swallowing difficulties, severe 
dysphonia and dysarthria, emotional lability, inspi-
ratory sighs, stereotyped moaning or groaning oc-
cur. Pseudobulbar palsy with slow spastic tongue 
movements, reduced gag reflex, brisk jaw and facial 
reflexes, are common findings. Severe nuchal rigid-
ity frequently precludes the performance of the doll’s 
eyes maneuver to establish the presence of a vertical 
supranuclear gaze palsy and is disproportionate to 
the moderately increased tone in the limbs. One 
fifth of patients have unilateral or bilateral positive 
Babinski sign.10 Unilateral limb dystonia or arm levi-
tations are observed in a minority of patients and 
do not equate to the presence of alien limb phenom-
enon, CBS or the underlying diagnosis of cortico-
basal degeneration.48,49 
Akinetic mutism, complete ophthalmoplegia, sig-
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nificant rigidity with or without contractures, immo-
bility are inevitably observed in the terminal disease. 
Pneumonia, respiratory failure, pulmonary embo-
lism and urinary tract infection are common causes 
of death.
PSP SUBTYPES
Clinicopathological studies have led to the recog-
nition of other clinical phenotypes associated with 
PSP-tau pathology. The clinical pictures of these PSP 
subtypes are most distinct in the first 2 years of pre-
sentation. As the disease progresses, overlap of clini-
cal features, emergence of new phenotype and tem-
poral evolution to the classic RS in later stages are 
frequently observed. RS is still considered as the 
classic and most frequent clinical presentation of 
cases with PSP-tau pathology, comprising of 50% or 
more of PSP cases with post-mortem confirmation.11 
The second most common subtype is PSP-P and 
may be observed in up to a third of all PSP cases.10 
PSP-PAGF, cortical PSP variants (PSP-CBS, PSP-
bvFTD, PSP-PNFA) and the recently described PSP-
C are relatively rare and each phenotypic subtype 
makes up of less than 5% of all PSP cases. A multi-
centre clinicopathological series reported clinical 
heterogeneity beyond a pure RS in the majority (87%) 
of cases within the first two years of presentation, 
and almost 40% of cases could not be classified into 
a particular phenotype.50 This study implies that het-
erogeneous presentations may be more common in 
PSP than has previously been indicated by other 
series in the literature and highlights the need for 
effective diagnostic biomarkers.51 
Globular glial tauopathies (GGTs) are a group of 
4-repeat tauopathies characterised neuropathologi-
cally by widespread, globular glial inclusions (GGIs) 
with the latter being predominantly negative for Gal-
lyas silver staining in contrast to the Gallyas-posi-
tive tau lesions in PSP.52 The clinical presentations 
of GGTs are heterogeneous with clinical diagnoses 
ranging from frontotemporal dementia, Pick’s dis-
ease, PSP, CBS, motor neuron disease (MND) and 
primary lateral sclerosis.52 A subgroup of GGT was 
previously referred as atypical PSP with corticospi-
nal tract degeneration (PSP-CST).53 It is now in-
creasingly recognized that this condition, previously 
referred as PSP-CST,53 sporadic multiple system 
tauopathy with dementia54 and sporadic 4R tauopa-
thy with frontotemporal lobar degeneration, parkin-
sonism and motor neuron disease (FTLD-P-MND),55 
all conform to the unified neuropathological diagno-
sis of GGT with GGIs being a consistent and defin-
ing histological feature. GGT is considered a patho-
logical entity that is distinct from PSP. 
PSP-P
This subgroup is frequently misdiagnosed clini-
cally as Parkinson’s disease. Patients with PSP-P 
presents with asymmetric limb bradykinesia and 
rigidity and do not have supranuclear vertical gaze 
palsy in the early stage.10 Patients may have a jerky 
postural tremor or a rest tremor. Half of the patients 
have moderate levodopa response but the benefit 
rarely sustains for more than a few years. As the dis-
ease advances, the clinical picture usually becomes 
more like RS. Early clinical pointers that favour 
PSP-P over Parkinson’s disease are rapid progres-
sion, prominent axial symptoms and an attenuated 
response to levodopa.10 The pattern of hypokinesia 
without decrement on repetitive finger tapping is 
another clue to the diagnosis of PSP.30 Falls and 
cognitive decline occur later in PSP-P than in PSP-
RS and are considered favourable prognostic features 
which may explain a longer survival of an average 
of 9 years in PSP-P.14 
A proportion of patients have overlapped features 
of both Parkinsonism (asymmetric bradykinesia, 
levodopa response, rigidity and tremor) and RS (early 
postural instability, subtle eye movement abnor-
malities and frontal subcortical deficits) in the early 
stages, but are categorised as PSP-P because of the 
predominant clinical picture of asymmetrical Par-
kinsonism. In a small number of patients, a pure 
Parkinson’s disease-like syndrome predominates 
until death and eye movement abnormalities never 
appear.10,56 A sustained levodopa response, levodo-
pa-induced choreiform dyskinesia and long disease 
duration characterise this far end of the clinical 
spectrum of PSP-P. Until clinical diagnostic criteria 
for PSP subtypes is available, the antemortem diag-
nosis of PSP-P relies on careful clinical examina-
tion, accurate clinical documentation, diagnostic 
revision and in some cases, a correct prediction of 
PSP pathology may not be possible without post-
mortem. 
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PSP-PAGF
PAGF is characterised by pronounced gait igni-
tion failure and start hesitation which remains as 
the isolated clinical picture for several years.13 Hy-
pophonia, facial hypomimia and fast micrographia 
may be subtle accompanying symptoms. As the 
condition progresses, freezing of gait, stuttering or 
stammering speech gradually develop. Axial rigidi-
ty and absence of limb rigidity are distinctive fea-
tures. Late features include slowing of vertical sac-
cades or vertical supranuclear gaze palsy, blepha-
rospasm, postural instability and falls are useful 
pointers for PSP-PAGF. Pronounced frontal subcor-
tical impairment, bradyphrenia, asymmetric bra-
dykinesia, rigidity, tremor, levodopa response are 
not observed in this phenotype. The median dis-
ease duration of PSP-PAGF is 11 years making this 
the most benign PSP subtype.11
Other underlying causes of a clinical presenta-
tion of PAGF are subcortical white matter isch-
aemia (Binswanger leukoaraiosis), normal pressure 
hydrocephalus,57 Parkinson’s disease and dementia 
with Lewy bodies. 
PSP-CBS
The underlying pathologies of CBS are heteroge-
neous but 70% of cases have a tauopathy including 
CBD and PSP.58 CBS, however, is a rare presentation 
of PSP and PSP-CBS comprises of only 4% of PSP 
cases.59
Patients with CBS present with progressive func-
tional difficulties with the use of one limb caused 
by a combination of limb apraxia, parietal sensory 
impairment, dystonia, myoclonus, levodopa-unre-
sponsive rigidity and bradykinesia and occasionally 
alien limb phenomenon.60 Delayed initiation of hori-
zontal saccades is characteristic for CBS and can be 
observed also in PSP-CBS and is more pronounced 
when gaze is directed toward the side of the apraxic 
limb.59 PNFA, apraxia of speech (AOS), orobuccal 
apraxia are common associated features.61,62 Pyra-
midal and Babinski’s signs are observed in half of 
PSP-CBS cases.59 Overlap of clinical features with 
RS is common especially in mid and late stages. Pos-
tural instability in the first year of disease onset, su-
pranculear downgaze palsy in patients with CBS are 
helpful clues to the underling PSP pathology. The 
median disease duration of PSP-CBS is 7.3 years, the 
same as PSP-RS.
PSP-PNFA
PNFA is a language disorder characterised by 
nonfluent speech with hesitancy, agrammatism and 
phonemic errors can be the predominant and so-
metimes isolated clinical presentation of PSP.61 It is 
frequently accompanied by AOS which is a motor 
speech disorder featuring slow, segmented and gro-
ping speech with errors in timing and abnormal pro-
sody.61 Progressive agraphia is sometimes a pre-
senting feature preceding the speech impairment.63 
PNFA and AOS may also be observed in other ph-
enotypes such as RS, CBS and bvFTD, but when 
both PNFA and AOS co-exist as the predominant 
clinical features, it is highly suggestive of FTLD-tau 
as the underlying pathology.61 PNFA in isolation 
without AOS is associated with FTLD-tau (includ-
ing PSP, CBD and Pick’s) in over 50%, FTLD-TAR 
DNA-binding protein-43 (FTLD-TDP)64 in 20%, and 
some cases with FTLD-TDP pathology may carry 
progranulin mutation or C9orf72 expansion.65 Other 
pathologies such as Alzheimer’s disease and de-
mentia with Lewy bodies have also been reported as 
the cause of PNFA.66
PSP-bvFTD
The most common cause of bvFTD is FTLD-TDP 
but other causes are recognized including Pick’s dis-
ease, CBD, PSP, Alzheimer’s disease or familial Al-
zheimer’s disease.64 Only less than 4% of bvFTD cas-
es have PSP pathology.67 Insidious behavioural, per-
sonality changes, emotional blunting, lack of em-
pathy, aggressive outbursts, distractibility, hyper-
phagia, neglected hygiene, socially inappropriate, 
disinhibited and compulsive behaviours and loss of 
insight are characteristic features. Typical features of 
RS may emerge in later stages and if present are use-
ful clinical pointers to the underling PSP pathology.68
PSP-C
Cerebellar ataxia as the predominant early pre-
senting feature is increasingly recognized as a very 
rare subtype of PSP (PSP-C) which is associated with 
severe neuronal loss with gliosis and higher densi-
Clinical Approach to PSP
 Ling H
www.e-jmd.org  9
ties of coiled bodies in the cerebellar dentate nucle-
us compared to PSP-RS.69,70 Reported cases with pa-
thologically confirmed PSP-C are mostly Japan-
ese,69,71 akin to the prevalent cerebellar subtype of 
MSA in that region. The clinical findings of pro-
gressive truncal and limb ataxia in PSP-C are dis-
tinct from unsteadiness due to postural instability 
observed in classic RS.69 Cardinal features of PSP 
may be observed early in the disease and are even-
tually present in all PSP-C cases. A Japanese series 
of 4 PSP-C cases identified that older age of onset 
(PSP-C: 68.8 ± 4.4 years vs. MSA-C: 58.3 ± 7.4 
years), early falls within the first 2 years, vertical su-
pranuclear gaze palsy without dysautonomia were 
predictive of PSP-C in individuals with late onset 
cerebellar ataxia.69 
INVESTIGATIONS
Differentiate diagnoses especially potentially tr-
eatable causes should be considered when assessing 
patients with postural instability and supranuclear 
gaze palsy. Conventional MRI of the brain is useful 
to exclude extensive cerebrovascular disease, leuko-
dystrophy, normal pressure hydrocephalus, structur-
al midbrain lesions and, rarely, manganese intoxi-
cation (with T1 hyperinstensity in globus pallidus) 
which can all masquerade as PSP. Laboratory tests 
for syphilis and HIV serology, autoimmune profile, 
paraneoplastic disease autoantibodies (e.g., Ma an-
tibodies72), antibodies for stiff-person syndrome (in-
cluding DPPX-IgG73) and Niemann Pick Type C 
may be considered. Cerebrospinal fluid (CSF) study 
of PCR for Tropheryma Whipplei is occasionally 
sent. In patients with rapid disease progression from 
symptom onset to akinetic mutism in less than a 
year, CSF14-3-3 protein, cortical high signal on dif-
fusion-weighted MRI images and diffuse slowing of 
EEG without or without periodic triphasic waves 
are suggestive of Creutzfeldt-Jakob disease.74 CSF 
neurodegenerative biomarkers for Alzheimer’s dis-
ease including an elevated total tau protein and re-
duced β-amyloid 1-42 protein support the diagnosis 
of Alzheimer’s disease.75 A CSF study suggested that 
C and N terminal fragments of tau are promising 
biomarkers of PSP pathology.76 Early disease onset, 
positive family history77 or concurrent clinical syn-
drome such as MND or FTD may point to mutations 
in MAPT,78 progranulin79 or C9orf72 expansion.80 
In specialist centres, formal neuropsychometry 
testing is routinely arranged to assess the perform-
ance of different cognitive domains. Swallowing as-
sessment and, in patients with more advanced dis-
ease, video fluoroscopy are valuable investigations 
to identify and manage patients who are at risk of 
aspiration.
NEUROIMAGING
Atrophy of the midbrain and superior cerebellar 
peduncle and dilatation of the third ventricle are the 
characteristic findings of PSP on conventional MRI.81 
Midbrain atrophy is increasingly recognized as a 
radiological marker for a clinical RS phenotype but 
it is not predictive of PSP pathology.82 The hum-
mingbird sign on the midsagittal plane with rostral 
midbrain atrophy and concavity is observed in 67% 
of pathologically confirmed PSP cases.83 Midbrain to 
pons ratio of less than 0.52 using AP diameter mea-
surements was useful to differentiate PSP-RS from 
MSA, however, no PSP subtypes were included in 
the study.84
Diffusion tensor imaging studies showed white 
matter tract degeneration especially in the superior 
cerebellar peduncles and superior longitudinal fas-
ciculus has been associated with RS.85 Functional 
MRI studies consistently demonstrated disruption 
of network connectivity between the cerebellum, 
midbrain, thalamus and premotor cortex.86 
Focal midbrain hypometabolism on fluorodeox-
yglucose (FDG)-positron emission tomography 
(PET) has been identified in patients with typical 
PSP, referred to as the pimple sign which corresponds 
to midbrain atrophy on MRI and can be considered 
as a radiological biomarker for the clinical RS phe-
notype.87 Another study showed that this focal mid-
brain region together with the caudate, thalamus 
and supplementary motor area are affected in patho-
logically confirmed PSP-RS cases.88
Dopamine transporter single photon emission 
computed tomography (SPECT) imaging shows re-
duced tracer uptake in the striatum which is a useful 
finding to differentiate PSP from other mimics such 
as cerebrovascular disease and normal pressure hy-
drocephalus.89 PET imaging with tau ligand is a 
promising radiologic tool for diagnostic and longi-
tudinal follow-up.90
10
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TREATMENT
Most specialist centres give trials of levodopa and 
amantadine but unfortunately their symptomatic 
benefits are limited.91 Zolpidem, a GABA agonist, 
may improve motor function, dysarthria and ocular 
abnormalities according to anecdotal evidence from 
case reports.92 Selective serotonin re-uptake inhibi-
tors (SSRIs) are effective at treating depression, ob-
sessive-compulsive behaviour and emotional lability 
but may worsen apathy.93 Memantine may provide 
symptomatic benefit in patients with PNFA.94 
Botulinum toxin injection to the pretarsal muscles 
is effective to alleviate eye closure symptoms in pa-
tients with blepharospasm and apraxia of eyelid op-
ening. Regular administration of artificial tears is be-
neficial for eye irritation and dry eyes. Gastrostomy 
feeding introduced in an appropriate disease stage 
is helpful to maintain nutrition, hydration and pre-
vent significant weight loss and aspiration pneumo-
nia, however, suitable counselling of the patients and 
relatives is essential to ensure an informed decision 
is made. 
A multidisciplinary team approach with input of 
swallowing and language therapist, dietician, phys-
iotherapist, psychologist, palliative care team, occu-
pational therapist and social worker (allocation of 
local health care service) is extremely important to 
ensure the needs of the patients are met. The chari-
ty-led support group such as PSP association in the 
UK is a valuable resource for families, caregivers 
and patients (http://www.pspassociation.org.uk/).
Disease-modifying therapeutic trials in the past 
years have improved our insights in the natural co-
urse of this devastating disorder.95-98 Although these 
trial medications have not proven to be effective, 
recent knowledge in tau seeding, propagations and 
strains in PSP and other tauopathies will lead to 
potential new therapeutic targets to halt the disease 
progression.99 
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